| 2024 |
Reply to: “irLI or not irLI: That is the question” |
Lettera |
Vai |
| 2024 |
Palliative care in patients with hepatocellular carcinoma: Results from a survey among hepatologists and palliative care physicians |
Articolo in rivista |
Vai |
| 2024 |
Prediction of cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenib |
Articolo in rivista |
Vai |
| 2024 |
Indolent cancer and pattern of progression: Two missing parameters in trial design for hepatology |
Articolo in rivista |
Vai |
| 2024 |
Sorafenib and Metronomic Capecitabine in Child-Pugh B patients with advanced HCC: A real-life comparison with best supportive care |
Articolo in rivista |
Vai |
| 2024 |
EASL position paper on clinical follow-up after HCV cure |
Articolo in rivista |
Vai |
| 2024 |
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab |
Articolo in rivista |
Vai |
| 2024 |
Multidisciplinary treatment of hepatocellular carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) – Part II – Non-surgical treatments |
Articolo in rivista |
Vai |
| 2024 |
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma |
Articolo in rivista |
Vai |
| 2024 |
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab |
Articolo in rivista |
Vai |
| 2024 |
What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg-negative anti-HBc-positive patients? Meta-analysis and decision curve analysis |
Review essay (rassegna critica) |
Vai |
| 2024 |
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study |
Articolo in rivista |
Vai |
| 2024 |
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours |
Articolo in rivista |
Vai |
| 2024 |
Initial uptake of durvalumab with or without tremelimumab for advanced hepatocellular carcinoma in routine clinical practice: Preliminary results of the international DT-real study |
Abstract in atti di convegno pubblicato in rivista |
Vai |
| 2023 |
Inflammation and autonomic balance in cirrhosis: Association between sympathetic nervous system and osteopontin, interleukin-22, interleukin-6 and interleukin-1Ra concentrations according to portal hypertension and disease severity |
Articolo in rivista |
Vai |
| 2023 |
Analysis of individual patient data in patients with HCC treated with immunotherapy: A step forward for clinical trial design |
Nota o commento |
Vai |
| 2023 |
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma |
Articolo in rivista |
Vai |
| 2023 |
Systemic treatment for hepatocellular carcinoma beyond milan criteria on the waitlist: is it time for a neoadjuvant therapy? |
Lettera |
Vai |
| 2023 |
The prognostic role of tumour progression and liver function at progression under immunotherapy for hepatocellular carcinoma |
Nota o commento |
Vai |
| 2023 |
Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database |
Articolo in rivista |
Vai |
| 2023 |
Predictors of non-transplantable recurrence in hepatocellular carcinoma patients treated with frontline liver resection |
Articolo in rivista |
Vai |
| 2023 |
Heart rate variability is associated with disease severity and portal hypertension in cirrhosis |
Articolo in rivista |
Vai |
| 2023 |
Multidisciplinary Treatment of Hepatocellular Carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) - Part I - Surgical treatments |
Articolo in rivista |
Vai |
| 2023 |
Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced HCC: the dark side of the moon |
Nota o commento |
Vai |
| 2023 |
Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept |
Review essay (rassegna critica) |
Vai |
| 2023 |
Balancing Efficacy and Tolerability of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis |
Articolo in rivista |
Vai |
| 2023 |
Radiological endpoints as surrogates for survival benefit in hepatocellular carcinoma trials: All that glitters is not gold |
Nota o commento |
Vai |
| 2023 |
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients |
Articolo in rivista |
Vai |
| 2023 |
Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma |
Articolo in rivista |
Vai |
| 2022 |
Benign liver lesions 2022: Guideline for clinical practice of Associazione Italiana Studio del Fegato (AISF), Società Italiana di Radiologia Medica e Interventistica (SIRM), Società Italiana di Chirurgia (SIC), Società Italiana di Ultrasonologia in Medicina e Biologia (SIUMB), Associazione Italiana di Chirurgia Epatobilio-Pancreatica (AICEP), Società Italiana Trapianti d'Organo (SITO), Società Italiana di Anatomia Patologica e Citologia Diagnostica (SIAPEC-IAP) - Part II - Solid lesions |
Articolo in rivista |
Vai |
| 2022 |
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis |
Articolo in rivista |
Vai |
| 2022 |
Impact of SARS-CoV-2 Pandemic on the Management of Patients with Hepatocellular Carcinoma |
Articolo in rivista |
Vai |
| 2022 |
Adjusting Barcelona Clinic Liver Cancer Staging System to the Evolving Landscape of Hepatocellular Carcinoma: A Look to the Future |
Articolo in rivista |
Vai |
| 2022 |
Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study |
Articolo in rivista |
Vai |
| 2022 |
Role of LI-RADS Indeterminate Observations in the Risk of Hepatocellular Carcinoma after HCV Eradication with Direct-Acting Antivirals |
Articolo in rivista |
Vai |
| 2022 |
RESIST-HCV Criteria to Monitor Progression of Low-Risk Esophageal Varices in Patients With Compensated Cirrhosis After HCV Eradication: The SIMPLE Study: SIMPLE: Scoring Index to Monitor Progression of Low-risk Esophageal varices |
Articolo in rivista |
Vai |
| 2022 |
Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study |
Articolo in rivista |
Vai |
| 2022 |
Clinical update on risks and efficacy of anti-SARS-CoV-2 vaccines in patients with autoimmune hepatitis and summary of reports on post-vaccination liver injury |
Articolo in rivista |
Vai |
| 2022 |
Benign liver lesions 2022: Guideline for clinical practice of Associazione Italiana Studio del Fegato (AISF), Società Italiana di Radiologia Medica e Interventistica (SIRM), Società Italiana di Chirurgia (SIC), Società Italiana di Ultrasonologia in Medicina e Biologia (SIUMB), Associazione Italiana di Chirurgia Epatobilio-Pancreatica (AICEP), Società Italiana Trapianti d'Organo (SITO), Società Italiana di Anatomia Patologica e Citologia Diagnostica (SIAPEC-IAP) - Part I - Cystic lesions |
Articolo in rivista |
Vai |
| 2022 |
Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma |
Articolo in rivista |
Vai |
| 2022 |
COSMIC-312: mounting immunotherapy enigmas for hepatocellular carcinoma |
Lettera |
Vai |
| 2022 |
Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function |
Articolo in rivista |
Vai |
| 2022 |
HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis |
Articolo in rivista |
Vai |
| 2022 |
The quest for precision oncology with immune checkpoint inhibitors for hepatocellular carcinoma |
Articolo in rivista |
Vai |
| 2022 |
Direct-acting antiviral agents and risk of Hepatocellular carcinoma: Critical appraisal of the evidence |
Articolo in rivista |
Vai |
| 2022 |
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib |
Articolo in rivista |
Vai |
| 2022 |
Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors |
Articolo in rivista |
Vai |
| 2022 |
The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints |
Articolo in rivista |
Vai |
| 2021 |
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: An individual patient data meta-analysis |
Articolo in rivista |
Vai |
| 2021 |
Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma |
Articolo in rivista |
Vai |
| 2021 |
Management of liver disease in Italy after one year of the SARS-CoV-2 pandemic: A web-based survey |
Articolo in rivista |
Vai |
| 2021 |
Long-term evolution of LI-RADS observations in HCV-related cirrhosis treated with direct-acting antivirals |
Articolo in rivista |
Vai |
| 2021 |
Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort |
Articolo in rivista |
Vai |
| 2021 |
Changes in hepatocellular carcinoma aggressiveness characteristics with an increase in tumor diameter |
Articolo in rivista |
Vai |
| 2021 |
SARS-CoV-2 infection in patients with a normal or abnormal liver |
Articolo in rivista |
Vai |
| 2021 |
Pattern of macrovascular invasion in hepatocellular carcinoma |
Articolo in rivista |
Vai |
| 2021 |
The changing scenario of hepatocellular carcinoma in Italy: an update |
Articolo in rivista |
Vai |
| 2021 |
First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials |
Articolo in rivista |
Vai |
| 2021 |
Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization |
Articolo in rivista |
Vai |
| 2021 |
Overview of prognostic systems for hepatocellular carcinoma and ITA.LI.CA external validation of MESH and CNLC classifications |
Articolo in rivista |
Vai |
| 2021 |
Systemic therapies for hepatocellular carcinoma: The present and the future |
Articolo in rivista |
Vai |
| 2021 |
Surveillance for hepatocellular carcinoma with a 3-months interval in “extremely high-risk” patients does not further improve survival |
Articolo in rivista |
Vai |
| 2021 |
Antiviral therapy in the palliative setting of HCC (BCLC-B and -C) |
Articolo in rivista |
Vai |
| 2021 |
Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib |
Articolo in rivista |
Vai |
| 2021 |
Treatment of hepatocellular carcinoma with immune checkpoint inhibitors and applicability of first-line atezolizumab/bevacizumab in a real-life setting |
Articolo in rivista |
Vai |
| 2021 |
A nomogram-based prognostic model for advanced hepatocellular carcinoma patients treated with sorafenib: A multicenter study |
Articolo in rivista |
Vai |
| 2021 |
Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma |
Articolo in rivista |
Vai |
| 2021 |
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib |
Articolo in rivista |
Vai |
| 2020 |
Is hepatocellular carcinoma risk impacted favorably or unfavorably by hepatitis C virus therapy with direct‐acting antivirals? |
Capitolo o Saggio |
Vai |
| 2020 |
Optimizing sequential systemic therapies for advanced hepatocellular carcinoma: A decision analysis |
Articolo in rivista |
Vai |
| 2020 |
Sicily Network for Liver Cancer: A Multidisciplinary Network Model for the Management of Primary Liver Tumors |
Articolo in rivista |
Vai |
| 2020 |
Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma |
Articolo in rivista |
Vai |
| 2020 |
Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib |
Articolo in rivista |
Vai |
| 2020 |
Hepatocellular carcinoma with macrovascular invasion: Multimodality imaging features for the diagnosis |
Articolo in rivista |
Vai |
| 2020 |
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib |
Articolo in rivista |
Vai |
| 2020 |
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma |
Articolo in rivista |
Vai |
| 2019 |
Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients |
Abstract in atti di convegno pubblicato in rivista |
Vai |
| 2019 |
Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients |
Articolo in rivista |
Vai |
| 2019 |
Risk Factors for Rate of Relapse and Effects of Steroid Maintenance Therapy in Patients With Autoimmune Pancreatitis: Systematic Review and Meta-analysis |
Articolo in rivista |
Vai |
| 2018 |
Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules |
Articolo in rivista |
Vai |
| 2018 |
Direct-acting antiviral agents and risk of hepatocellular carcinoma: is it still a clinical dilemma? |
Articolo in rivista |
Vai |
| 2018 |
Gadoxetic acid-enhanced MRI of transient hepatic enhancement differences: Another cause of hypointense observation on hepatobiliary phase |
Articolo in rivista |
Vai |
| 2017 |
HBV virological suppression: Still not enough to save from hepatocellular carcinoma. A case report on a 15-year, real-life story |
Articolo in rivista |
Vai |
| 2017 |
Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study |
Articolo in rivista |
Vai |
| 2017 |
A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma |
Articolo in rivista |
Vai |
| 2017 |
Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response |
Articolo in rivista |
Vai |
| 2016 |
Magnetic resonance imaging of the cirrhotic liver in the era of gadoxetic acid |
Articolo in rivista |
Vai |
| 2016 |
The cheating liver: imaging of focal steatosis and fatty sparing |
Articolo in rivista |
Vai |
| 2016 |
MR-imaging features of hepatocellular carcinoma capsule appearance in cirrhotic liver: comparison of gadoxetic acid and gadobenate dimeglumine |
Articolo in rivista |
Vai |
| 2015 |
Computed tomography of bowel obstruction: Tricks of the trade |
Articolo in rivista |
Vai |
| 2015 |
Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: A systematic review and meta-analysis |
Articolo in rivista |
Vai |
| 2015 |
Second line systemic therapies for hepatocellular carcinoma: Reasons for the failure |
Articolo in rivista |
Vai |
| 2014 |
Focal lesions in cirrhotic liver: what else beyond hepatocellular carcinoma? |
Articolo in rivista |
Vai |
| 2014 |
Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C |
Articolo in rivista |
Vai |
| 2014 |
Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results. |
Articolo in rivista |
Vai |
| 2014 |
Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C |
Articolo in rivista |
Vai |
| 2014 |
Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C |
Articolo in rivista |
Vai |
| 2013 |
Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C |
Articolo in rivista |
Vai |
| 2013 |
Hepatocellular carcinoma and synchronous liver metastases from colorectal cancer in cirrhosis: A case report. |
Articolo in rivista |
Vai |
| 2013 |
Rise and fall of HCV-related hepatocellular carcinoma in Italy: a long-term survey from the ITA.LI.CA centres. |
Articolo in rivista |
Vai |
| 2013 |
Chemoprevention for hepatocellular carcinoma: the role of statins |
Articolo in rivista |
Vai |
| 2013 |
A rs4374383 Single Nucleotide Polymorphisms of MERTK gene is linked to a higher likelihood of hepatocellular carcinoma in patients with HCV cirrhosis |
Abstract in rivista |
Vai |
| 2013 |
Imaging appearance of treated hepatocellular carcinoma. |
Articolo in rivista |
Vai |
| 2013 |
Treatment of hepatocellular carcinoma: present and future. |
Articolo in rivista |
Vai |
| 2013 |
Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. |
Articolo in rivista |
Vai |
| 2013 |
Primary biliary cirrhosis and hereditary hemorrhagic
telangiectasia: When two rare diseases coexist |
Articolo in rivista |
Vai |
| 2012 |
Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study |
Articolo in rivista |
Vai |
| 2012 |
Imaging findings of liver resection using a bipolar radiofrequency electrosurgical device-Initial observations. |
Articolo in rivista |
Vai |
| 2012 |
"Should cirrhosis change our attitude towards treating non-hepatic cancer?" |
Articolo in rivista |
Vai |
| 2012 |
Letter: liver dysfunction and survival in hepatocellular carcinoma treated by transarterial chemoembolisation - authors' reply |
Articolo in rivista |
Vai |
| 2012 |
Reply to: Sorafenib in clinical practice: Evidence-based use or abuse? |
Articolo in rivista |
Vai |
| 2011 |
Predicting survival in patients with hepatocellular carcinoma
treated by transarterial chemoembolisation |
Articolo in rivista |
Vai |
| 2011 |
Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib. |
Articolo in rivista |
Vai |
| 2011 |
Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. |
Articolo in rivista |
Vai |
| 2010 |
Update on new approaches in the management of hepatocellular carcinoma. |
Articolo in rivista |
Vai |
| 2010 |
Epidemiology, risk factors and surveillance of hepatocellular carcinoma |
Articolo in rivista |
Vai |
| 2010 |
Cost analysis of recall strategies for non-invasive diagnosis of small hepatocellular carcinoma |
Articolo in rivista |
Vai |
| 2010 |
A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. |
Articolo in rivista |
Vai |
| 2009 |
Prognostic scores for hepatocellular carcinoma: none is the winner. |
Articolo in rivista |
Vai |
| 2009 |
L'impiego del Tachosil in chirurgia epatica |
Articolo in rivista |
Vai |
| 2009 |
Multimodal approaches to the treatment of hepatocellular carcinoma. |
Articolo in rivista |
Vai |
| 2009 |
Hepatocellular Cancer: Optimal
Strategies for Screening and Surveillance |
Articolo in rivista |
Vai |
| 2009 |
Retreatment with pegylated interferon plus ribavirin of chronic
hepatitis C non-responders to interferon plus ribavirin: A meta-analysis. |
Articolo in rivista |
Vai |
| 2008 |
Seeding after radiofrequency ablation of hepatocellular carcinoma in patients with cirrhosis: a prospective study. |
Articolo in rivista |
Vai |
| 2008 |
Long-Term Course of Chronic Hepatitis C in Children: From Viral Clearance to
End-Stage Liver Disease |
Articolo in rivista |
Vai |
| 2008 |
Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems |
Articolo in rivista |
Vai |
| 2007 |
Seeding after radiofrequency thermal ablation of hepatocellular carcinoma in cirrhosis: a prospective study |
Proceedings |
Vai |
| 2007 |
Mortality in patients with hepatocellular carcinoma predicted by six scoring: none is the winner |
Proceedings |
Vai |
| 2007 |
The impact of radiotherapy on survival in resectable gastric carcinoma: A meta-analysis of literature data. |
Articolo in rivista |
Vai |
| 2007 |
Sicurezza ed efficacia della chemioembolizzazione arteriosa transcatetere nel trattamento dei pazienti con epatocarcinoma: studio triennale di 75 pazienti italiani |
Proceedings |
Vai |
| 2005 |
Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study |
Articolo in rivista |
Vai |
| 2005 |
Radio-frequency thermal ablation (RFTA) of small hepatocellular carcinoma in patients with cirrhosis. Experience at a single tertiary referral center |
Articolo in rivista |
Vai |
| 2005 |
Treatment of hepatitis C: critical appraisal of the evidence |
Articolo in rivista |
Vai |
| 2004 |
L'impiego del Tissue-Link FB3.0 floating ball nelle resezioni epatiche |
Proceedings |
Vai |
